arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Allogene Therapeutics, Inc.

ALLO

$2.01 ▲ +0.04 (+2.29%) at close

9 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Allogene Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $443.5M

Dividend Yield —

Revenue Growth N/M

Op. Margin —

ROIC -71.6% ↘

FCF / Share $-0.68 ↗

Trailing P/E —

Price / Book 1.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-190.89M

↑ +25.9% —

FCF / Share Free cash flow per share

$-0.68

↑ +34.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2017

$0.00

FY 2018

$0.00

FY 2019

$0.00

FY 2020

$0.00

FY 2021

$0.00

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	N/M	-76.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1061%)	-39.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-589%)	-99.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1345%)	—	—	—	—	—
EPS Growth YoY (%)	34.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	36.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	12.2% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-25.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	9.1% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	25.9% Excellent ↓ Excellent Declining Year-over-year change in net income	21.3% Good ↑ Good Improving Year-over-year change in net income	3.9% Caution ↑ Caution Improving Year-over-year change in net income	62.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-261.0% Weak ↓ Weak Declining Year-over-year change in net income	-35.6% Weak Weak Year-over-year change in net income	12.7% Fair Fair Year-over-year change in net income	—	—
FCF Growth YoY (%)	34.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	32.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	3.3% Caution ↑ Caution Improving Year-over-year change in free cash flow	-3.8% Weak Weak Year-over-year change in free cash flow	-1.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	—	-91.7% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-71.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-64.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-64.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.9% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-23.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-32.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-27.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-50.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-21.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-24.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-65.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-535%)	-61.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-507%)	-63.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-526%)	-45.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-405%)	-98.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-757%)	-23.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-255%)	-29.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-296%)	-30.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-301%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	-57.43x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-51.69M	$-75.22M	$-83.16M	$-74.36M	$-173.31M	$-183.35M	$-175.13M	$-92.43M	—

📊 What does each share earn? 8 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.28	$0.00	—	—	—
Basic EPS, GAAP (USD)	$-0.87	$-1.32	$-2.09	$-2.38	$-1.89	$-2.08	—	—	—
Free Cash Flow per Share (USD)	$-0.68	$-1.03	$-1.52	$-1.58	$-1.52	$-1.50	—	—	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—
Book Value per Share (USD)	$1.28	$1.99	$3.04	$5.16	$6.43	$7.69	$5.06	$5.79	$0.00
Tangible Book Value per Share (USD)	$1.28	$1.99	$3.04	$5.16	$6.43	$7.69	$5.06	$5.78	$0.00
Basic Weighted Avg Shares (shares)	220.62M	194.81M	156.93M	143.15M	135.82M	120.37M	—	—	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$225.24M	$267.86M	$422.04M	$520.98M	$423.15M	$750.81M	$511.50M	$438.52M	—
Total Equity (USD)	$292.54M	$422.18M	$512.23M	$743.40M	$916.41M	$1.08B	$629.02M	$703.16M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$22.00K	$95.00K	$156.00K	$38.49M	$0.00	—	—	—
Depreciation Expense (USD)	$12.36M	$13.64M	$14.20M	$14.30M	$10.50M	$7.40M	$4.60M	$1.00M	—
Net Income, GAAP (USD)	$-190.89M	$-257.59M	$-327.26M	$-340.41M	$-903.30M	$-250.22M	$-184.59M	$-211.50M	—
Operating Cash Flow (USD)	$-149.25M	$-200.30M	$-237.73M	$-220.52M	$-184.81M	$-115.09M	$-137.35M	$-44.65M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

Allogene Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ALLO with peers